CSIMarket Company Name, Ticker, Suppliers, else..
 
Seres Therapeutics Inc   (NASDAQ: MCRB)
Other Ticker:  
 
 
Price: $0.8621 $-0.03 -2.818%
Day's High: $0.925 Week Perf: 12.34 %
Day's Low: $ 0.85 30 Day Perf: -5.26 %
Volume (M): 1,279 52 Wk High: $ 1.53
Volume (M$): $ 1,103 52 Wk Avg: $0.90
Open: $0.89 52 Wk Low: $0.54



 Market Capitalization (Millions $) 132
 Shares Outstanding (Millions) 153
 Employees 150
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -25
 Cash Flow (TTM) (Millions $) -101
 Capital Exp. (TTM) (Millions $) 1

Seres Therapeutics Inc
Seres Therapeutics Inc is a biotechnology company that specializes in the development of microbiome therapeutics. The company focuses on researching and utilizing the microorganisms that reside in the human gut to develop innovative therapies for various diseases. Seres Therapeutics aims to treat serious diseases by targeting the microbiome, which plays a crucial role in our immune system, metabolism, and overall health. The company's goal is to harness the power of the microbiome to improve the lives of patients suffering from conditions such as inflammatory bowel disease, infectious diseases, and metabolic disorders. Seres Therapeutics is headquartered in Cambridge, Massachusetts and was founded in 2010.


   Company Address: 101 Cambridgepark Drive Cambridge 2140 MA
   Company Phone Number: 945-9626   Stock Exchange / Ticker: NASDAQ MCRB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
APRE      % 
TSVT      % 
• View Complete Report
   



Management Announcement

Seres Therapeutics Finalizes VOWST Sale to Nestlé Health Science Amid Financial Losses, Focuses on Advancing Live Biotherapeutics Development,

Published Mon, Sep 30 2024 9:15 PM UTC

In a landmark strategic move, Seres Therapeutics, Inc. (Nasdaq: MCRB), headquartered in Cambridge, Massachusetts, has successfully completed the sale of its VOWST business to Societé des Produits Nestlé S.A., a subsidiary of Nestlé Health Science. This decision comes as part of Seres? broader strategy to align its resources on the development of its core offerings, particula...
Clinical Study

Seres Therapeutics Stockholders Approve Sale of VOWST to Nestl Health Science; Sale Expected to Close on September 30

Published Thu, Sep 26 2024 8:01 PM UTC

Seres Therapeutics Gains Stockholder Endorsement for VOWST Sale to Nestlé Health Science, Anticipated Closure by Month-EndIn a strategic move that underscores the evolving landscape of biotherapeutics, Seres Therapeutics, Inc. (Nasdaq: MCRB), headquartered in Cambridge, Massachusetts, has announced the successful approval of its shareholders for the sale of its VOWST busine...
Clinical Study

SER-155 Shows Promise in Reducing Infection Rates and Antibiotic Use Post-Allogeneic Hematopoietic Stem Cell Transpla...

Published Thu, Sep 12 2024 11:00 AM UTC

Abstract Seres Therapeutics has reported promising findings from its Phase 1b placebo-controlled trial evaluating SER-155 in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study demonstrated that SER-155 administration was significantly associated with a reduction in bacterial bloodstream infections (BSIs), systemic antibiotic exposur...
Contract

Seres Therapeutics Secures $175M Lifeline through Nestlé Health Science Partnership Amid Plummeting Revenues...

Published Tue, Aug 6 2024 11:00 AM UTC

Seres Therapeutics, a pioneering biotechnology company focused on developing microbiome therapeutics, has recently announced a significant financial move through an asset purchase agreement with Nestlé Health Science. This strategic deal, valued at $175 million, marks a crucial juncture for Seres amidst a notable revenue downturn. This article delves into the facets of the a...
Shares

Seres Therapeutics Harnesses the Power of Equity Grants to Fuel Innovation and Retain Top Talent

Published Fri, Jun 7 2024 8:00 PM UTC


Seres Therapeutics Grants Inducement Equity to New Employee, Boosting Future Potential
CAMBRIDGE, Mass, June 07, 2024 - Seres Therapeutics, a renowned microbiome therapeutics company, recently announced the granting of inducement equity to a new employee by its Compensation and Talent Committee. The total equity grant encompasses 6,188 shares of Seres common stock,...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com